PURPOSE: The United Kingdom's "Yellow Card Scheme" for reporting of adverse drug reactions (ADRs) has been operating for 50 years, but reporting rates by community pharmacists remain low. The aim of the study was therefore to investigate the views and experiences of ADR reporting by community pharmacists in Wales, with a particular focus on the potential barriers and facilitators to reporting. METHODS: Following ethics approval and piloting, a self-complete questionnaire was mailed to all registered community pharmacies in Wales, UK (n = 713). A follow-up mailing was sent to nonresponders after 2 weeks. RESULTS: A response rate of 52% (n = 372) was achieved, of whom 57% had never submitted a yellow card. Key barriers to reporting were not seeing ADRs, difficulty identifying the causative drug, not being sure which ADRs to report, and lack of time. Key facilitators were being able to report through dispensary software and having clearer guidelines about what to report. Differences between those who had previously reported ADRs and those who had not suggested lack of confidence and uncertainty about what to report were more of a barrier for nonreporters. Conversely, reporters wanted feedback on reports, ability to keep reports on their dispensary records, and remuneration to aid them with reporting. CONCLUSIONS: While the respondents generally expressed positive attitudes towards ADR reporting, a number of barriers and potential facilitators were nevertheless identified. Clearer support and guidance for reporting, such as through a "champions" scheme similar to that run in Welsh hospitals, may help current nonreporters to engage.
PURPOSE: The United Kingdom's "Yellow Card Scheme" for reporting of adverse drug reactions (ADRs) has been operating for 50 years, but reporting rates by community pharmacists remain low. The aim of the study was therefore to investigate the views and experiences of ADR reporting by community pharmacists in Wales, with a particular focus on the potential barriers and facilitators to reporting. METHODS: Following ethics approval and piloting, a self-complete questionnaire was mailed to all registered community pharmacies in Wales, UK (n = 713). A follow-up mailing was sent to nonresponders after 2 weeks. RESULTS: A response rate of 52% (n = 372) was achieved, of whom 57% had never submitted a yellow card. Key barriers to reporting were not seeing ADRs, difficulty identifying the causative drug, not being sure which ADRs to report, and lack of time. Key facilitators were being able to report through dispensary software and having clearer guidelines about what to report. Differences between those who had previously reported ADRs and those who had not suggested lack of confidence and uncertainty about what to report were more of a barrier for nonreporters. Conversely, reporters wanted feedback on reports, ability to keep reports on their dispensary records, and remuneration to aid them with reporting. CONCLUSIONS: While the respondents generally expressed positive attitudes towards ADR reporting, a number of barriers and potential facilitators were nevertheless identified. Clearer support and guidance for reporting, such as through a "champions" scheme similar to that run in Welsh hospitals, may help current nonreporters to engage.
Authors: Renly Lim; Lisa Kalisch Ellett; Elizabeth E Roughead; Phaik Yeong Cheah; Nashwa Masnoon Journal: Int J Environ Res Public Health Date: 2021-11-12 Impact factor: 4.614
Authors: Ar Kar Aung; Steven Walker; Yin Li Khu; Mei Jie Tang; Jennifer I Lee; Linda Velta Graudins Journal: Eur J Clin Pharmacol Date: 2022-02-16 Impact factor: 2.953